STAT June 21, 2024
Elizabeth Cooney

ORLANDO — The United States is at a critical juncture in its efforts to treat chronic diseases, particularly type 2 diabetes, and now has a chance to change the dangerous trajectory it’s currently following, FDA Commissioner Robert Califf said Friday.

“The U.S. is leading the world in technology development, innovation, new gadgets of all kinds, new drugs, you name it,” he said. “These advantages unfortunately are not resulting in superior health and outcomes for the U.S., population, or for most individuals in the U.S.”

Health outcomes as a whole are deteriorating in the U.S., Califf said in his remarks at the American Diabetes Association conference, but he sees one outlier.

“There’s an exception for type 1 diabetes, which I believe...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Digital Health, FDA, Govt Agencies, Patient / Consumer, Provider, Technology, Wearables
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article